NDA 021064 · Lantheus Medcl
Definity
Perflutren · Intravenous · Contrast Agent for Ultrasound Imaging
NovelLast checked: Nov 20, 2026Latest source record: Mar 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Jul 31, 2001
Approved uses
3
Original approval plus efficacy supplements
Registered trials
112
12 Phase 3, 18 recruiting
FAERS reports
5,709
1,899 serious, 116 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes DEFINITY RT administration [see Contraindications (4) ] . Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1) ] . WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes DEFINITY RT administration ( 4 ). Always have resuscitation...
What it is approved for
From the label in effect Mar 13, 2024.
DEFINITY RT is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. DEFINITY RT is an ultrasound contrast agent indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. ( 1 )
Mechanism: Perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood. These physical acoustic properties of activated DEFINITY RT provide contrast enhancement of the left ventricular chamber and aid delineation of the left ventricular endocardial border during echocardiography. In animal models the acoustic properties of activated DEFINITY were established at or below a mechanical index of 0.7 (1.8 MHz frequency). In clinical trials, the majority of the patients were imaged at or below a mechanical index of 0.8.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 1, 2024 Supplement 33 · Efficacy LabelLetter
- Oct 24, 2011 Supplement 11 · Efficacy Summary ReviewLabelReview
- Jul 31, 2001 Original approval · Type 1 - New Molecular Entity NovelReviewLabelOther Important Information from FDA
2 products under this application
- DEFINITY · PERFLUTREN 13.04MG/2ML (6.52MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
- DEFINITY RT · PERFLUTREN 13.04MG/2ML (6.52MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Perflutren" as an intervention, any sponsor and status, largest first.
Lantheus Medical ImagingIndustry
NCT00625365 · 1,060 participants · Start Feb 2008 · Primary completion May 2009
Drug: DEFINITY® · For: Cardiovascular Disease
Sites: San Diego, California; Newark, Delaware; Chicago, Illinois · 16 sites in all
GE HealthcareIndustry
NCT00730964 · 1,039 participants · Start May 2008 · Primary completion Oct 2009
Drug: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP) · For: Echocardiography
Sites: Princeton, New Jersey
- Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; RenewalPivotal-lookingRecruiting
Thomas Jefferson UniversityAcademic, hospital or other
NCT05470205 · 660 participants (planned) · Start Nov 28, 2022 · Primary completion Feb 28, 2028
Drug: SHAPE measurement (Sonazoid ultrasoud contrast agent); SHAPE measurement (Definity ultrasoud contrast agent) · For: Liver Diseases; Portal Hypertension
Sites: Philadelphia, Pennsylvania; Bern, Switzerland · 3 sites in all
Lantheus Medical ImagingIndustry
NCT00162370 · 400 participants · Start Apr 2004 · Primary completion Sep 2012
Drug: Perflutren Lipid Microsphere Injectable Suspension · For: Coronary Artery Disease; Heart Disease
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
- Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate CancerPivotal-lookingNot yet recruiting
Thomas Jefferson UniversityAcademic, hospital or other
NCT06024772 · 300 participants (planned) · Start Jan 2027 · Primary completion Aug 1, 2027
Drug: Perflutren lipid microsphere · For: Prostate Carcinoma
Sites: Philadelphia, Pennsylvania
Thomas Jefferson UniversityAcademic, hospital or other
NCT01490892 · 219 participants · Start Nov 2011 · Primary completion Apr 5, 2019
Drug: 3D HI and SHI of UCA · For: Breast Cancer
Sites: La Jolla, California; Philadelphia, Pennsylvania
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT06185972 · 200 participants (planned) · Start Jul 25, 2024 · Primary completion Feb 1, 2026
Drug: Definity · For: Breast Cancer
Sites: Toronto, Canada
- A Study of Renal Microvessel Imaging for Chronic Kidney DiseaseEnrolling by invitation
Mayo ClinicAcademic, hospital or other
NCT05764642 · 186 participants (planned) · Start Aug 9, 2023 · Primary completion Apr 1, 2028
Drug: Definity · For: Healthy; Chronic Kidney Diseases
Sites: Jacksonville, Florida; Rochester, Minnesota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- back pain2,424
- dyspnoea800
- muscle spasms755
- pain in extremity504
- flushing414
- chest pain403
- headache382
- dizziness331
- urticaria305
- neck pain304
- nausea274
- arthralgia244
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 135 |
| 2005 | 195 |
| 2006 | 342 |
| 2007 | 628 |
| 2008 | 279 |
| 2009 | 35 |
| 2010 | 31 |
| 2011 | 15 |
| 2012 | 23 |
| 2013 | 29 |
| 2014 | 20 |
| 2015 | 64 |
| 2016 | 244 |
| 2017 | 222 |
| 2018 | 187 |
| 2019 | 209 |
| 2020 | 252 |
| 2021 | 251 |
| 2022 | 501 |
| 2023 | 528 |
| 2024 | 509 |
| 2025 | 612 |
| 2026 | 398 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Definity RT* (Perflutren Lipid Microspheres*) · HCPCS Q9956
2024 spending
$710K
Beneficiaries
6,326
6,640 claims
Per beneficiary
$112
2024 ASP limit $42.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $426,133 |
| 2021 | $485,074 |
| 2022 | $512,081 |
| 2023 | $668,279 |
| 2024 | $709,638 |
Part B: Definity* (Perflutren Lipid Microspheres*) · HCPCS Q9957
2024 spending
$3.8M
Beneficiaries
47,123
49,594 claims
Per beneficiary
$80
2024 ASP limit $42.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,155,276 |
| 2021 | $3,525,808 |
| 2022 | $3,415,002 |
| 2023 | $3,593,091 |
| 2024 | $3,790,637 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke.
Alexandrov AV, Mikulik R, Ribo M, et al. · Stroke 2008 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Sonothrombolysis in ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.
Mathias W, Tsutsui JM, Tavares BG, et al. · J Am Coll Cardiol 2019 · Comparative Study, Randomized Controlled Trial
- Qualitative and Quantitative Contrast-enhanced Endoscopic Ultrasound Improves Evaluation of Focal Pancreatic Lesions.
Buxbaum J, Ko C, Varghese N, et al. · Clin Gastroenterol Hepatol 2020 · Controlled Clinical Trial, Research Support, Non-U.S. Gov't
- Noninvasive Evaluation of Cardiac Chamber Pressures Using Subharmonic-Aided Pressure Estimation With Definity Microbubbles.
Esposito C, Machado P, McDonald ME, et al. · JACC Cardiovasc Imaging 2023 · Clinical Trial, Research Support, N.I.H., Extramural
- Detection of coronary stenoses at rest with myocardial contrast echocardiography.
Wei K, Tong KL, Belcik T, et al. · Circulation 2005 · Clinical Trial, Research Support, N.I.H., Extramural
- Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images.
Kitzman DW, Goldman ME, Gillam LD, et al. · Am J Cardiol 2000 · Clinical Trial, Comparative Study
Sponsor: Lantheus Medcl · Also marketed as Definity Rt
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.